Synapse - September 2019
by multiple authors
Webinar: Recent legislative developments affecting biologics and biosimilars
The Court of Justice on skinny labels
No compulsory licence for Sanofi's Praluent in Germany
SPC manufacturing waiver for export and stockpiling comes into force
Recent legislative developments affecting biologics and biosimilars
by multiple authors
Brexit update – 'Grandfathering' marketing authorisations
Essentially biological processes and their products – what is patentable?
Biosimilars webinar series – Recent developments in biosimilars settlements, market landscape and antitrust scrutiny
by multiple authors
Plausibility of second medical use patents: pregabalin in the Supreme Court
The grant of an SPC for a new therapeutic application
Infringement of second medical use patents in the UK: pregabalin in the Supreme Court